Key Stats for Novo Nordisk Stock
- 1- month price change for Novo Nordisk stock: 11%
- $NVO Share Price as of May. 15: $45
- 52-Week High: $81
- $NVO Stock Price Target: $47
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Novo Nordisk (NVO) stock is in focus this week after the company confirmed it plans to go “all in” on launching its Wegovy weight loss pill outside the United States later this year.
Emil Kongshøj Larsen, Novo’s EVP for International Operations, told CNBC bluntly: “When we launch, we’ll go all in. It’s a major opportunity.”
The U.S. launch has been a standout success.
- Since debuting in January, the Wegovy pill has generated over 2 million total prescriptions in just 16 weeks. More than 1 million patients are now using it.
- Weekly scripts hit 207,000 by mid-April — a record-breaking pace for any GLP-1 drug launch in the U.S. About 80% of users are patients who had never tried a GLP-1 drug before.
Novo also raised its 2026 guidance slightly, though it still expects sales and profits to decline between 4% and 12% for the full year. Lower U.S. prices and generic competition in markets like Canada, India, and China are the main pressures.
Despite that, Q1 obesity care sales rose 22%, and the pill’s sales beat expectations even at its lower price point.
The global rollout won’t be identical to the U.S. launch. Larsen noted that pricing dynamics differ significantly across markets.
In most countries, patients pay out of pocket — even in countries with socialized healthcare. He said the international sales curve may be “slightly more bent” compared to the sharp U.S. ramp.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free) >>>
What the Market Is Telling Us About Novo Nordisk Stock
Novo Nordisk stock is navigating a competitive moment. Eli Lilly launched its rival oral pill Foundayo in April, but early prescription data suggest the Wegovy pill is well ahead.
Eli Lilly CEO David Ricks acknowledged the brand buildup would “take quarters, not days.”
Analysts at Barclays noted that the two pills appear to target different patient segments, with Wegovy showing stronger efficacy and Foundayo positioned more as an entry-level option.
The bigger opportunity is clear: roughly 1 billion people globally could benefit from these medications, but only about 20 million are currently being treated.
That gap is what makes Novo Nordisk stock worth watching closely as international launches unfold.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Novo Nordisk Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
